Home > Topoisomerase & > Topotecan HCl

Topotecan HCl

盐酸拓扑替康,托泊替康,NSC609699, Nogitecan HCl,SKFS 104864A

Topotecan Hydrochloride ( SKF104864) 是靶向拓扑异构酶I的细胞毒性剂，已进入临床试验。

目录号
EY1243
EY1243
EY1243
EY1243
纯度
99.38%
99.38%
99.38%
99.38%
规格
5 mg
10 mg
50 mg
100 mg
原价
290
480
1200
2100
售价
290
480
1200
2100
库存
现货
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Topotecan (synonym: NSC609699, Nogitecan HCl, SKFS 104864A) is a topoisomerase I inhibitor for MCF-7 Luc cells and DU-145 Luc cells with IC50 of 13 nM and 2 nM, respectively.

  • 体外研究

  • 体内研究

    Saline

  • 激酶实验

  • 细胞实验

    0 μg/mL - 0.692 μg/mL

  • 动物实验

    0.25 mg/mL腹腔注射给药

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Caceres G, et al. Anticancer Drugs. 2003, 14(7), 569-574.
    [2] Uckun, F.M., et al. 1995. Blood. 85: 2817-2828.
    [3] Arun, B., et al. 2001. Expert Opin Pharmacother. 2: 491-505.

    分子式
    C23H24ClN3O5    		 分子量
    457.91    		 CAS号
    119413-54-6    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    92 mg/mL    		 Water
    92 mg/mL    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT01037023 Lung Cancer, Small Cell Drug: Topotecan GlaxoSmithKline 2010-10-01 2015-04-14
    NCT02303028 Solid Tumors|Central Nervous System Tumors Drug: Topotecan and Pazopanib The Hospital for Sick Children|C17 Council Phase 1|Phase 2 2015-03-01 2016-10-17
    NCT01840943 Epithelial Ovarian Cancer Drug: CAELYX|Drug: Topotecan HCl Xian-Janssen Pharmaceutical Ltd. Phase 3 2013-06-01 2015-11-17
    NCT02100007 Solid Tumors Drug: ME-344|Drug: Topotecan MEI Pharma, Inc.|SCRI Development Innovations, LLC Phase 1|Phase 2 2014-04-01 2016-07-01
    NCT00002395 HIV Infections|Leukoencephalopathy, Progressive Multifocal Drug: Topotecan SmithKline Beecham|NIH AIDS Clinical Trials Information Service Phase 2 null 2005-06-23
    NCT00611468 Metastatic Solid Tumor Drug: Topotecan|Drug: Erlotinib Accelerated Community Oncology Research Network|GlaxoSmithKline|Genentech, Inc. Phase 1 2006-06-01 2011-08-18
    NCT02278510 Malignant Glioma|WHO Grade III or IV Recurrent Glioma Drug: Topotecan|Drug: Gadolinium DTPA|Device: Cleveland Multiport Catheter Michael Vogelbaum, MD, PhD|Infuseon Therapeutics, Inc.|Case Comprehensive Cancer Center Early Phase 1 2014-12-01 2016-09-19
    NCT00294190 Small Cell Lung Cancer|Carcinoma, Small Cell Drug: Topotecan SCRI Development Innovations, LLC|GlaxoSmithKline Phase 2 2006-02-01 2012-12-06
    NCT00382733 Tumors Drug: Oral Topotecan Accelerated Community Oncology Research Network|GlaxoSmithKline Phase 1|Phase 2 2006-11-01 2013-07-17
    NCT01003938 Ovarian Cancer Drug: Topotecan|Drug: Erlotinib New York University School of Medicine|OSI Pharmaceuticals Phase 2 2009-08-01 2016-05-31
    NCT00390806 Lung Cancer, Non-Small Cell Drug: HYCAMTIN, oral capsules|Radiation: Radiation GlaxoSmithKline Phase 3 2006-12-01 2013-12-05
    NCT02500459 Brain Tumor|High Grade Glioma Drug: topotecan Michael Vogelbaum, MD, PhD|Infuseon Therapeutics, Inc.|Case Comprehensive Cancer Center Early Phase 1 2015-07-01 2016-01-26
    NCT02963090 Small Cell Lung Cancer Drug: Topotecan|Drug: Pembrolizumab Alliance Foundation Trials, LLC.|Merck Sharp & Dohme Corp. Phase 2 2016-12-01 2016-11-10
    NCT00158886 Rectal Cancer Drug: Hycamtin GlaxoSmithKline Phase 1 2001-11-01 2009-05-21
    NCT02649673 Small Cell Lung Cancer|Ovarian Cancer Drug: LCL161|Drug: Topotecan SCRI Development Innovations, LLC|Novartis Pharmaceuticals Phase 1|Phase 2 2016-03-01 2016-09-26
    NCT01600573 Ovarian Cancer Drug: pazopanib in combination with weekly topotecan JSehouli|GlaxoSmithKline|Charite University, Berlin, Germany Phase 1|Phase 2 2012-05-01 2016-10-10
    NCT00610571 Glioblastoma|Gliosarcoma|Anaplastic Astrocytoma Drug: Oral Topotecan and Temodar Katy Peters|GlaxoSmithKline|Schering-Plough|Duke University Phase 1 2004-04-01 2013-10-23
    NCT00483860 Lung Cancer, Small Cell Drug: Topotecan GlaxoSmithKline Phase 1 2007-06-01 2012-10-25
    NCT00365547 Lung Cancer Biological: bevacizumab|Drug: topotecan hydrochloride Masonic Cancer Center, University of Minnesota Phase 2 2006-09-01 2012-07-31
    NCT01736800 Central Nervous System (CNS) Metastases|Brain Metastases Drug: Topotecan|Drug: Temozolomide The Methodist Hospital System Phase 2 2007-03-01 2013-06-18
    NCT00308165 Brain Neoplasms, Primary Malignant Procedure: Convection-Enhanced Delivery|Drug: Topotecan Jeffrey N. Bruce|Columbia University Phase 1|Phase 2 2004-03-01 2015-01-13

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：